




# ACTA PHARMACEUTICA SINICA B

The Journal of the [Institute of Materia Medica](#), the [Chinese Academy of Medical Sciences](#) and the [Chinese Pharmaceutical Association](#)

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Editorial Board</b>	<b>p.1</b>
●	<b>Guide for Authors</b>	<b>p.4</b>



ISSN: 2211-3835

### DESCRIPTION

*Acta Pharmaceutica Sinica B* (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.

APSB is a series of journal of Acta Pharmaceutica Sinica, which was founded in 1953, indexed in Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, Current Bibliography on Science and Technology, etc. It sponsored by [Institute of Materia Medica](#), [Chinese Academy of Medical Sciences](#) and [Chinese Pharmaceutical Association](#), production and hosting by Elsevier B. V.

### EDITORIAL BOARD

#### *Editor-in-Chief*

**J.D. Jiang**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

#### *Associate Editors-in-Chief*

**Shi-Lin Chen**, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China

**Xin-xin Ding**, Colleges of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, New York, USA

**De-an Guo**, Shanghai Inst. of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China

**Long-qin Hu**, Dept. of Medicinal Chemistry, State University of New Jersey, Piscataway, New Jersey, USA

**Rong-guang Shao**, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Jian-Gong Shi**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Xiao-liang Wang**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Jian-ping Ye**, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA

**Qiang Zhang**, Sch. of Pharmaceutical Sciences, Peking University, Beijing, China

#### *Academic Consultants*

**David W. Boykin**, Dept. of Chemistry, Georgia State University, Atlanta, Georgia, USA

**Yung-Chi Cheng**, Department of Pharmacology, Yale University, New Haven, Connecticut, USA

**Jian Ding**, Shanghai Institute of Materia Medica, Chinese Academy of Medical Sciences, Shanghai, China

**Zong-ru Guo**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Chang-xiao Liu**, Tianjin Institute of Pharmaceutical Research, Tianjin, China  
**Pei-gen Xiao**, Inst. of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing, China  
**Bao-feng Yang**, Dept. of Pharmacology, Harbin Medical University, Harbin, Heilongjiang, China  
**De-quan Yu**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Yong-su Zhen**, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College  
**Hong-hao Zhou**, Central South University, Changsha, China  
**Tong-hui Zhou**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Editorial Board Member**

**Zeper Abliz**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Suresh V. Ambudkar**, Laboratory of Cell Biology, CCR, NCI, NIH, National Cancer Institute (NCI), Bethesda, , Maryland, USA  
**Jozef Anné**, Rega Institute, Leuven, Belgium  
**Giovanni Battista Appendino**, Fac. of Pharmacy, Università degli Studi del Piemonte Orientale, Novara, Italy  
**Rudolf Bauer**, Inst. of Pharmaceutical Sciences, Dept. of Pharmacognosy, Karl-Franzens-Universität Graz, Graz, Austria  
**Kai-shun Bi**, Shenyang Pharmaceutical University, Shenyang, China  
**Diane Burgess**, School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA  
**Shan Cen**, Inst. of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China  
**Arpana Sagwal Chaudhary**, Intellectual Property Consultant, Life Sciences, Walnut Creek, CA, USA  
**Chun-tao Che**, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois, USA  
**Dao-Feng Chen**, Department of Chemistry, Fudan University, Shanghai, China  
**Fener Chen**, Department of Chemistry, Fudan University, Shanghai, China  
**Guan Chen**, Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA  
**Jason Chen**, College of Pharmacy and Health Sciences, St. John's University, New York, New York, USA  
**Jian-guo Chen**, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  
**Tao-sheng Chen**, Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA  
**Xiao-guang Chen**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Mao-sheng Cheng**, Shenyang Pharmaceutical University, Shenyang, China  
**Jun-gui Dai**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Erik De Clercq**, Rega Institute, Leuven, Belgium  
**De-li Dong**, Dept. of Pharmacology, Harbin Medical University, Harbin, Heilongjiang, China  
**Guan-hua Du**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Dayue Darrel Duan**, School of Medicine, Center of Molecular Medicine, University of Nevada, Reno, Nevada, USA  
**Liang Fang**, Shenyang Pharmaceutical University, Shenyang, China  
**John P. Fawcett**, University of Otago, Dunedin, New Zealand  
**Li-Wu Fu**, Cancer Centre, Sun Yat-Sen University, Guangzhou, China  
**Zhong-gao Gao**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Margherita Gavagnin**, Consiglio Nazionale delle Ricerche (CNR), Istituto di Chimica Biomolecolare, Napoli, Italy  
**Ruxandra Gref**, Fac. of Pharmacy, Université Paris-Sud (Paris XI), Châtenay-Malabry, France  
**Jing-kai Gu**, Jilin University, Changchun, China  
**Xiang-ming Guan**, South Dakota State University, Brookings, South Dakota, USA  
**Yue-Wei Guo**, Shanghai Institute of Materia Medica, Chinese Association of Sciences, Shanghai, China  
**Hai-ping Hao**, China Pharmaceutical University, Nanjing, China  
**Lang-chong He**, Xi'an Jiaotong University, Xi'an, China  
**David W. Hein**, University of Louisville, Louisville, Kentucky, USA  
**Michael Heinrich**, UCL School of Pharmacy, University of London, London, UK  
**Gang Hu**, Nanjing University, Nanjing, China  
**Zhuo-wei Hu**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Zi-chun Hua**, Nanjing University, Nanjing, China  
**Leaf Huang**, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Wilmington, North Carolina, USA  
**Lu-qi Huang**, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China  
**Magnus Ingelman-Sundberg**, Karolinska Institutet, Stockholm, Sweden

**Han-Chang Kang**, Catholic University of Korea, Seoul, The Republic of Korea  
**Ling-yi Kong**, Dept. of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China  
**Tibor Kurtán**, Dept. of Organic Chemistry, University of Debrecen, Debrecen, Hungary  
**Ping Lee**, Leslie Dan Fac. of Pharmacy, University of Toronto, Toronto, Ontario, Canada  
**Chuan Li**, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China  
**Shaoping Li**, Inst. of Chinese Medical Sciences, University of Macau, Macao, China  
**Wei Li**, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA  
**Ya-ping Li**, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China  
**Zhuo-rong Li**, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Jing-gen Liu**, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China  
**Hai-bin Luo**, School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, China  
**Yu-Kyoung Oh**, College of Pharmacy, Seoul National University (SNU), Seoul, The Republic of Korea  
**Zui Pan**, The Ohio State University, Columbus, Ohio, USA  
**Joachim Stöckigt**, Johannes Gutenberg Universität Mainz, Mainz, Germany  
**Hong-bin Sun**, China Pharmaceutical University, Nanjing, China  
**Xun Sun**, West China School of Pharmacy, Sichuan University, Chengdu, China  
**Orazio Tagliatalata-Scafati**, Dipartimento di Farmacia, Università di Napoli Federico II, Napoli, Italy  
**Hiroshi Tomoda**, Graduate School of Pharmaceutical Sciences, Kitasato University, Tokyo, China  
**Paul Vanhoutte**, Dept. of Pharmacology, Li Ka Fac. of Medicine, The University of Hong Kong, Hong Kong, China  
**Bing-he Wang**, Department of Chemistry, Georgia State University, Atlanta, Georgia, USA  
**Hong-bing Wang**, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA  
**Ke-wei Wang**, Peking University Health Science Center, Beijing, China  
**Ming-wei Wang**, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China  
**Wei Wang**, Department of Chemistry, University of New Mexico, Albuquerque, New Mexico, USA  
**Chuan-bin Wu**, School of Pharmaceutical Science, Sun Yat-Sen University, Guangzhou, China  
**Chuan-Yu Wu**, University of Surrey, Surrey, England, UK  
**Jian-hui Wu**, McGill University, Montreal, Quebec, Canada  
**Jun Wu**, City of Hope National Medical Center, Duarte, California, USA  
**Hong-bin Xiao**, Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Dalian, China  
**Wen Xie**, Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA  
**Hong-xi Xu**, Shanghai University of Traditional Chinese Medicine, Shanghai, China  
**Ming-shi Yang**, University of Copenhagen, Copenhagen, Denmark  
**Sheng-yong Yang**, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China  
**Peter York**, Pharmaceutical Technology School of Pharmacy, University of Bradford, Bradford, UK  
**Qi-dong You**, China Pharmaceutical University, Nanjing, China  
**Ai-ming Yu**, School of Medicine, University of California, Davis, Sacramento, California, USA  
**Lei Yu**, Sch. of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China  
**Shan-ping Yu**, Department of Anesthesiology, Emory University School of Medicine, Atlanta, USA  
**Shi-Shan Yu**, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China  
**Su Zeng**, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China  
**Ao Zhang**  
**Ji-wen Zhang**, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China  
**Liang-ren Zhang**, Peking University School of Pharmaceutical Sciences, Beijing, China  
**Zhong-Zhen Zhao**, Hong Kong Baptist University  
**Xiao-bo Zhong**, University of Connecticut, Storrs, Connecticut, USA  
**Zhi-Yuan Zhong**, Soochow University, Suzhou, China  
**Hua Zhu**, The Ohio State University, Columbus, Ohio, USA

## GUIDE FOR AUTHORS

---

### **Submission checklist**

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files* (where applicable)

*Supplemental files* (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

### **BEFORE YOU BEGIN**

#### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

#### **Human and animal rights**

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association](#) (Declaration of Helsinki) for experiments involving humans; [Uniform Requirements for manuscripts submitted to Biomedical journals](#). Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

#### **Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [CrossCheck](#).

### **Contributors**

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### **Clinical trial results**

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

#### *Reporting clinical trials*

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The [CONSORT checklist and template flow diagram](#) are available online.

#### *Registration of clinical trials*

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with [International Committee of Medical Journal Editors](#) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

## **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

## **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### *Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

## **Open access**

Every peer-reviewed research article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. The author does not have any publication charges for open access. The Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association will pay to make the article open access.

A CC user license manages the reuse of the article (see <http://www.elsevier.com/openaccesslicenses>). All articles will be published under the following license:

### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

### *Elsevier Publishing Campus*

The Elsevier Publishing Campus ([www.publishingcampus.com](http://www.publishingcampus.com)) is an online platform offering free lectures, interactive training and professional advice to support you in publishing your research. The College of Skills training offers modules on how to prepare, write and structure your article and explains how editors will look at your paper when it is submitted for publication. Use these resources, and more, to ensure that your submission will be the best that you can make it.

### *Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

### *Submission*

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail. Telephone Support for Chinese speaking users is available. Call at +86 10 85208780 or email at [liuyin@imm.ac.cn](mailto:liuyin@imm.ac.cn) (Available from 9:00 to 17:30 CST)

### *Referees*

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

## **PREPARATION**



## Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## Article structure

### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Theory/calculation*

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-

case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

#### *Graphical abstract*

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### *Abbreviations*

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

#### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.



### *Nomenclature and units*

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult [IUB: Biochemical Nomenclature and Related Documents](#) for further information.

### *Math formulae*

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

## **Artwork**

### *Electronic artwork*

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

## **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

## **References**

### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference style*

The titles of journals should be abbreviated according to the "List of Journals Indexed" in Index Medicus ([www.nlm.nih.gov](http://www.nlm.nih.gov)). List all authors, for more than 6 authors the first 6 should be listed followed by "et al."

*Text:* Indicate references by superscript numbers) in the text. The actual authors can be referred to, but the reference number(s) must always be given.

*List:* Number the references in the list in the order in which they appear in the text.

### *Examples:*

Reference to a journal publication:

1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. *J Sci Commun* 2000;163:51–9.

Reference to a book:

2. Strunk Jr W, White EB. *The elements of style*. 3rd ed. New York: Macmillan; 1979.

Reference to a chapter in an edited book:

3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. *Introduction to the electronic age*. New York: E-Publishing Inc; 1999, p. 281–304.

For further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (*J Am Med Assoc* 1997;277:927–934) (see also [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)).

### *Journal abbreviations source*

Journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

## **Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB in total. Any single file should not exceed 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#).

Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

### **RESEARCH DATA**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

#### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

#### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

#### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **AFTER ACCEPTANCE**

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication.

### **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2014 Elsevier | <http://www.elsevier.com>